194 related articles for article (PubMed ID: 21575221)
1. Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274.
Hou J; Dong J; Sun L; Geng L; Wang J; Zheng J; Li Y; Bridge J; Hinrichs SH; Ding SJ
J Transl Med; 2011 May; 9():64. PubMed ID: 21575221
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma.
Kenessey I; Keszthelyi M; Krámer Z; Berta J; Adám A; Dobos J; Mildner M; Flachner B; Cseh S; Barna G; Szokol B; Orfi L; Kéri G; Döme B; Klepetko W; Tímár J; Tóvári J
Curr Cancer Drug Targets; 2010 May; 10(3):332-42. PubMed ID: 20370683
[TBL] [Abstract][Full Text] [Related]
3. c-Met is a potentially new therapeutic target for treatment of human melanoma.
Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
[TBL] [Abstract][Full Text] [Related]
4. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Ma PC; Jagadeeswaran R; Jagadeesh S; Tretiakova MS; Nallasura V; Fox EA; Hansen M; Schaefer E; Naoki K; Lader A; Richards W; Sugarbaker D; Husain AN; Christensen JG; Salgia R
Cancer Res; 2005 Feb; 65(4):1479-88. PubMed ID: 15735036
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death.
Lui VW; Wong EY; Ho K; Ng PK; Lau CP; Tsui SK; Tsang CM; Tsao SW; Cheng SH; Ng MH; Ng YK; Lam EK; Hong B; Lo KW; Mok TS; Chan AT; Mills GB
Oncogene; 2011 Mar; 30(9):1127-34. PubMed ID: 21057531
[TBL] [Abstract][Full Text] [Related]
6. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Seiwert TY; Jagadeeswaran R; Faoro L; Janamanchi V; Nallasura V; El Dinali M; Yala S; Kanteti R; Cohen EE; Lingen MW; Martin L; Krishnaswamy S; Klein-Szanto A; Christensen JG; Vokes EE; Salgia R
Cancer Res; 2009 Apr; 69(7):3021-31. PubMed ID: 19318576
[TBL] [Abstract][Full Text] [Related]
7. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
[TBL] [Abstract][Full Text] [Related]
8. Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth.
Inagaki Y; Qi F; Gao J; Qu X; Hasegawa K; Sugawara Y; Tang W; Kokudo N
Biosci Trends; 2011; 5(2):52-6. PubMed ID: 21572247
[TBL] [Abstract][Full Text] [Related]
9. Effect of c-Met inhibitor SU11274 on human colon cancer cell growth.
Gao SH; Liu C; Wei J; Feng Y
Chin Med J (Engl); 2013 Jul; 126(14):2705-9. PubMed ID: 23876900
[TBL] [Abstract][Full Text] [Related]
10. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
Sattler M; Pride YB; Ma P; Gramlich JL; Chu SC; Quinnan LA; Shirazian S; Liang C; Podar K; Christensen JG; Salgia R
Cancer Res; 2003 Sep; 63(17):5462-9. PubMed ID: 14500382
[TBL] [Abstract][Full Text] [Related]
11. Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma.
Gao W; Bing X; Li M; Yang Z; Li Y; Chen H
Med Oncol; 2013 Jun; 30(2):546. PubMed ID: 23536000
[TBL] [Abstract][Full Text] [Related]
12. Met receptor inhibitor SU11274 localizes in the endoplasmic reticulum.
Wiest EJ; Smith HJ; Hollingsworth MA
Biochem Biophys Res Commun; 2018 Jul; 501(4):858-862. PubMed ID: 29752941
[TBL] [Abstract][Full Text] [Related]
13. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion.
Koon EC; Ma PC; Salgia R; Welch WR; Christensen JG; Berkowitz RS; Mok SC
Int J Gynecol Cancer; 2008; 18(5):976-84. PubMed ID: 18021219
[TBL] [Abstract][Full Text] [Related]
14. Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.
Zimmer Y; Vaseva AV; Medová M; Streit B; Blank-Liss W; Greiner RH; Schiering N; Aebersold DM
Cancer Lett; 2010 Mar; 289(2):228-36. PubMed ID: 19783361
[TBL] [Abstract][Full Text] [Related]
15. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
Milligan SA; Burke P; Coleman DT; Bigelow RL; Steffan JJ; Carroll JL; Williams BJ; Cardelli JA
Clin Cancer Res; 2009 Aug; 15(15):4885-94. PubMed ID: 19638461
[TBL] [Abstract][Full Text] [Related]
16. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
[TBL] [Abstract][Full Text] [Related]
17. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.
Berthou S; Aebersold DM; Schmidt LS; Stroka D; Heigl C; Streit B; Stalder D; Gruber G; Liang C; Howlett AR; Candinas D; Greiner RH; Lipson KE; Zimmer Y
Oncogene; 2004 Jul; 23(31):5387-93. PubMed ID: 15064724
[TBL] [Abstract][Full Text] [Related]
18. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
[TBL] [Abstract][Full Text] [Related]
19. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.
Kim HJ; Yoon A; Ryu JY; Cho YJ; Choi JJ; Song SY; Bang H; Lee JS; Cho WC; Choi CH; Lee JW; Kim BG; Bae DS
Sci Rep; 2016 Dec; 6():38502. PubMed ID: 27917934
[TBL] [Abstract][Full Text] [Related]
20. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
